WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Genzyme

GenzymeGenzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

www.genzyme.com

Genzyme RSS Channel

Filters
List of articles in category Genzyme
Title Published Date
Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards 06 January 2016
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care 05 October 2015
Genzyme recognizes World MS Day 30 May 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients 22 January 2012
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration 16 November 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis 12 July 2011
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform 17 June 2011
Genzyme Revenues Grow in First-Quarter 2011 29 April 2011
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease 15 April 2011
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares 07 March 2011
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program 28 February 2011
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year 16 February 2011
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence 31 January 2011
Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme® 20 January 2011
Genzyme Financial Recovery Continues in Fourth Quarter 11 January 2011
Genzyme Statement on Discussions With Sanofi-Aventis 10 January 2011
Genzyme Details Market Potential of Alemtuzumab for MS 20 December 2010
Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer 13 December 2010
Genzyme Completes Sale of Genetic Testing Business to LabCorp 01 December 2010
Genzyme Announces Agreement to Sell Diagnostics Business 18 November 2010
  • Start
  • Prev
  • 1
  • 2
  • 3
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Genzyme

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.